The main purpose of this study is to evaluate the effect of itraconazole on the amount of LY3200882 in the blood stream and how long the body takes to get rid of LY3200882. The safety and tolerability of LY3200882 when given with itraconazole will be evaluated. The study is expected to last up to 19 days from the first dose to follow-up (inclusive). Screening will occur up to 28 days prior to enrollment.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
BASIC_SCIENCE
Masking
NONE
Enrollment
23
Administered orally.
Administered orally.
Covance Clinical Research Inc
Daytona Beach, Florida, United States
Pharmacokinetics (PK): Maximum Drug Concentration (Cmax) of LY3200882
PK: Cmax of LY3200882
Time frame: Baseline through 72 hours post-dose
PK: Area Under the Concentration Curve (AUC) of LY3200882
PK: AUC of LY3200882
Time frame: Baseline through 72 hours post-dose
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.